CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02 mai 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
26 avr. 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 mars 2024 16h39 HE
|
CytoSorbents
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
06 mars 2024 07h00 HE
|
CytoSorbents
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
08 févr. 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 janv. 2024 07h15 HE
|
CytoSorbents
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
08 janv. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cytosorbents Corporation...
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 déc. 2023 07h00 HE
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
13 déc. 2023 09h15 HE
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
09 nov. 2023 16h15 HE
|
CytoSorbents
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...